Hitachi’s radiotherapy equipment business surges on acquisitions from Mitsubishi Heavy and Mitsubishi Electric, pulling ahead of Toshiba and Sumitomo Heavy Industries through its “unique strategy”

Hitachi, Ltd.’s medical equipment business is strengthening its presence in radiotherapy equipment in Japan and overseas. Revenue from the business is expected to reach ¥285.4 billion in fiscal 2025, while adjusted operating profit is forecast to reach ¥43.5 billion, representing increases of slightly more than 13% and approximately 15%, respectively, from the previous year. This growth is viewed as the result of structural reforms, including Hitachi’s acquisitions in recent years of businesses from Mitsubishi Heavy Industries and Mitsubishi Electric.

While Hitachi previously transferred its diagnostic imaging business to Fujifilm, it has expanded its scale in cancer treatment through the acquisitions of businesses from Mitsubishi Heavy Industries and Mitsubishi Electric. The company is said to hold a top-tier share of the radiotherapy equipment market in Japan and overseas and to have become a driving force in the development of cancer treatment worldwide. The next page examines the secrets behind its strength and the challenges to future growth.

This feature article examines the competitive advantages of Hitachi’s radiotherapy equipment business in the medical equipment industry and the direction of its future growth.